PREDICTIVE DRUG TESTING IN ORGANOID MODELS

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

High-throughput screening (HTS) of approved and investigational agents in organoid models established from patient-derived tumor tissues. These studies will assist NCI in identifying drug responsive tumors and enable the active investigation of the underlying mechanism(s) of action, predictive biomarkers of response and/or resistance to agents, and the effects of genetic alterations on drug efficacy.